Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results

被引：3
|
作者：
Mitsunaga, Shuichi
Ikeda, Masafumi
Ueno, Hideki
Nakachi, Kohei
Morizane, Chigusa
Kondo, Shunsuke
Shimizu, Satoshi
Kojima, Yasushi
Suzuki, Takuya
Tamai, Toshiyuki
O'Brien, James P.
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Natl Ctr Global Hlth & Med, Tokyo, Japan
[4] Eisai, Tokyo, Japan
[5] Eisai, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
231
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies
    Gupta, A.
    Koetz, B.
    Hanekom, W.
    O'Brien, J. P.
    Wanders, J.
    Jansen, M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 143 - 143
  • [22] Plasma biomarkers predictive for disease control duration in the phase I study of E7080, a multitarget kinase inhibitor
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Goto, Y.
    Tanioka, M.
    Yamada, K.
    Koizumi, F.
    Koyama, N.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors
    Yamada, K.
    Hirata, T.
    Fujiwara, Y.
    Nokihara, H.
    Yamamoto, N.
    Yamada, Y.
    Koizumi, F.
    Nishio, K.
    Koyama, N.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] A phase IB study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
    Hong, David S.
    Andresen, Corina
    Mink, Jennifer
    Ren, Min
    O'Brien, James P.
    Ly Minh Nguyen
    Falchook, Gerald Steven
    Kurzrock, Razelle
    Nemunaitis, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part - Correlation between pharmacokinetics (PK) and hepatic dysfunction
    Furuse, J.
    Okusaka, T.
    Ishii, H.
    Nakachi, K.
    Suzuki, E.
    Shimizu, S.
    Ueno, H.
    Ikeda, M.
    Morizane, C.
    Ogura, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 275 - 275
  • [26] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Evans, T. R. Jeffry
    Basu, Bristi
    Hubner, Richard
    Ma, Yuk Ting
    Meyer, Tim
    Palmer, Daniel H.
    Pinato, David J. James
    Plummer, Elizabeth Ruth
    Ross, Paul J.
    Samson, Adel
    Sarker, Debashis
    Kendall, Timothy
    Bellamy, Christopher
    Reeves, Helen L.
    Thomson, Fiona
    Lawless, Claire A.
    Stobo, Jamie
    Sansom, Owen J.
    Mann, Derek A.
    Bird, Thomas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS631 - TPS631
  • [28] Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
    Yamada, Kazuhiko
    Yamamoto, Noboru
    Yamada, Yasuhide
    Nokihara, Hiroshi
    Fujiwara, Yutaka
    Hirata, Taizo
    Koizumi, Fumiaki
    Nishio, Kazuto
    Koyama, Noriyuki
    Tamura, Tomohide
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2528 - 2537
  • [29] A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC)
    Goyal, Lipika
    Wadlow, Raymond Couric
    Blaszkowsky, Lawrence Scott
    Wolpin, Brian M.
    Vasudev, Eamala
    Sheehan, Susan
    Knowles, Michelle
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Chen, L.
    Shiah, H. S.
    Chen, C. Y.
    Lin, Y. J.
    Lin, P. W.
    Su, W. C.
    Chang, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345